REPLReplimune, Inc.Signing up patients
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Hepatocellular Carcinoma · Biliary Tract Cancer
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +3.9
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 2
- Patients
- 60 (planned)
- Started
- Aug 1, 2024
- Main results expected
- Dec 1, 2027
- Fully finished
- Jul 1, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate per modified RECIST 1.1
Measured over: From Day 1 up to 3 years after first RP2 dose of last patient.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 3.9, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05733598 · record last updated 2026-04-02 · checked 2026-11-09 15:42 UTC